About us
Van Leeuwenhoeck Research (VLR) is an independent research company, enabling institutional investors and other professional investors to better understand the real value of innovative Life Sciences companies they invest in. VLR can tap into a selected circle of top analysts in L...
Published by: Rod Raynovich, GEN |
Date: 17 January 2010
Over 6,000 people piled into the Westin St. Francis Hotel in San Francisco for J.P. Morgan’s (JPM) “28th Annual Healthcare Conference.” Investors, company presenters, and entrepreneurs were emboldened by good biotech sector returns in 2009 of 18–28% with many stocks reaching new highs. Seasonality has been a factor with the so-called “January effect,” where small-cap stocks tend to spike for a number of reasons, this conference paramount among them. For example, the IBB ETF is up about 6% from November levels. Following are some brief notes from important companies presenting at JPM.
|
Published by: Joseph Kruger, Seeking Alpha |
Date: 17 January 2010
At the 28th annual JP Morgan Healthcare conference, which ran from January 11- January 14th 2010, there were more than 300 companies represented, making their presentations to more than 6000 public and private equity and venture capital investors. There was considerable enthusiasm for the sector this past week; it seemed like every biotech company rallied and closed the week up. But what will happen after the JP Morgan Healthcare Conference? Was the activity the last couple weeks just due to short term investor enthusiasm?
|